Troy Wichterman Sells 932 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 932 shares of the firm’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $20.11, for a total transaction of $18,742.52. Following the transaction, the chief financial officer now directly owns 188,310 shares of the company’s stock, valued at approximately $3,786,914.10. This represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, April 1st, Troy Wichterman sold 25,687 shares of BioLife Solutions stock. The shares were sold at an average price of $22.66, for a total value of $582,067.42.
• On Tuesday, March 11th, Troy Wichterman sold 4,151 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total transaction of $103,775.00.
• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total transaction of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total transaction of $4,219.86.

BioLife Solutions Price Performance

Shares of BLFS traded up $0.91 during midday trading on Friday, reaching $21.90. The stock had a trading volume of 596,266 shares, compared to its average volume of 373,805. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a market capitalization of $1.03 billion, a P/E ratio of -20.66 and a beta of 1.93. The firm’s 50 day moving average price is $25.04 and its 200-day moving average price is $25.34. BioLife Solutions, Inc. has a 52 week low of $14.84 and a 52 week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The firm had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the previous year, the business earned ($0.21) earnings per share. On average, analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of BioLife Solutions

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its position in BioLife Solutions by 40.8% in the third quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after buying an additional 5,638 shares during the last quarter. FMR LLC lifted its position in shares of BioLife Solutions by 470.6% during the 3rd quarter. FMR LLC now owns 13,317 shares of the medical equipment provider’s stock valued at $333,000 after acquiring an additional 10,983 shares during the last quarter. Stifel Financial Corp boosted its stake in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after acquiring an additional 670 shares in the last quarter. State Street Corp grew its holdings in shares of BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after acquiring an additional 95,788 shares during the last quarter. Finally, Barclays PLC raised its position in shares of BioLife Solutions by 20.1% during the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after purchasing an additional 10,803 shares during the period. 93.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. StockNews.com upgraded BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright boosted their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Benchmark reissued a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. KeyCorp lifted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Finally, Northland Securities increased their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.